Integration of SGLT2i in the Management of Patients With CKD PICO 3: In patients with CKD what is the role of novel anti-hyperglycemic agents compared with placebo for reduction of the composite of kidney death, progression to dialysis, or reduction of eGFR
With improved weight loss and the additional pleiotropic benefits of GIP, other metabolic risk factors are improved with tirzepatide
Estudios clnicos sugieren que dietas ricas en fibra fermentable y protenas de alta calidad pueden contribuir a mejoras en el control glucmico en personas con prediabetes o diabetes tipo 2
The expanding number of glucose-lowering interventionsfrom behavioural interventions to pharmacological interventions, devices and surgeryand growing information about their benefits and risks provide more options for people with diabetes and providers but complicate decision making
Ro has a dedicated insurance concierge team that handles prior authorizations, verifies your coverage, submits paperwork, and coordinates with your pharmacy
Meet the incredible doctors we've partnered with